OMICS International is glad to welcome all the interested participants to its 4th International Conference on Blood Malignancies and Treatment during April 18-20, 2016 at Dubai, UAE. The conference will be organized around the theme “Conquering blood cancer with contemporary precision therapeutics and restorative approaches”. Blood Malignancies 2016 welcomes the hematologists, immunologists, pathologists, oncologists, research scholars, industrial professionals and student delegates from biomedical and healthcare sectors to be a part of it.
Blood cancer is a type of cancer or tumor. Blood cancer affects the blood, bone marrow, lymph, and lymphatic system, sometimes more than one body part gets affected. It affects the production and function of your blood cells. Most of these cancers start in your bone marrow where blood is produced. Billions of people are suffering from blood cancers and millions are dying every year across the globe. Blood Malignancies 2016 will be an initiative to find the weapon to fight against the dreadful blood cancers, to protect and save lives. Discussions will be focused on the different types of blood cancers, possibility of early detection and treatment at the advanced stages of these cancers to prolong life.
To know about more Omics Group Conferences visit conference series.
OMICS International has an enhanced and highlighted features of scientific partnerships and alliances with development agencies, Institutes, leading research organizations, non-government organizations, and other entities to promote the development-oriented research across the globe through live streaming, B2B and Scientific Meetings. OMICS International’s Medical Conferences provides an excellent opportunity for the budding scientists and young researchers through its special initiatives like Young Researcher Forum, Poster Presentation and E-poster.
OMICS International Organizes 300+ Scientific Conferences every year across USA, Europe & Asia. Besides 500 Peer reviewed, Open Access Journals, OMICS International has collaborated with more than 1000 Scientific Associations and institutions worldwide to promote information on health care and technologies. These journals are enjoying the support of over 5 million readers; a team of 30,000 eminent scholars are providing editorial support.
Blood Malignancies 2016 is going to take place in Dubai, UAE the largest and most populous City of UAE. It will be a great opportunity for the participants to explore this beautiful city which comprises of beautiful architectural innovations as well as contemporary technological tourist attractions besides gaining and sharing knowledge in an international platform.
Unfortunately, blood cancer affects a large number of people. Every 20 minutes, one person in UK is detected with blood cancer, 70 people a day, and 25,000 people a year. According to the CDC, cancer is the second leading cause of mortality, causing 584,881 deaths worldwide in 2013. Early diagnosis is the key to prevent the rising number of cancer-related deaths. The global cancer diagnostics market is witnessing a rapid transformation owing to several technological advancements in diagnostic platforms such as next-generation sequencing, DNA microarrays, and polymerase chain reaction (PCR). Moreover, the market has seen the advent of hybrid imaging instruments with enhanced accuracy, such as PET/CT and SPECT/CT. These advancements have augmented the growth of the cancer diagnostics market. The global cancer diagnostics market is expected to reach $ 13.1 Billion in 2020 from an estimated $ 7.1 Billion in 2015, growing at a CAGR of 12.9%. The global tumor ablation market is poised to grow at a CAGR of 11.5% during 2014-2019, and is expected to reach a value of 462.0 Million in 2019.
Various Hematologic Malignancies
Hematologic malignancies are forms of cancer that begins in the cells of blood-forming tissue, such as the bone marrow, or in the cells of the immune system. Examples of hematologic cancer are acute and chronic leukemia, lymphomas, multiple myeloma and myelodysplastic syndromes. Myeloproliferative neoplasms, or MPNs, are hematologic cancers that arise from malignant hematopoietic myeloid progenitor cells in the bone marrow, such as the precursor cells of red cells, platelets and granulocytes. Proliferation of malignant progenitor cells leads to an overproduction of any combination of white cells, red cells and/or platelets, depending on the disease. These overproduced cells may also be abnormal, leading to additional clinical complications. Included in the MPN disease spectrum are essential thrombocythemia (ET), polycythemia Vera (PV) and myelofibrosis (MF).
This scientific session will focus on all types of common or rare blood cancers such as acute promyelocytic leukemia(APL) and chronic myelomonocytic leukemia (CMML),hairy cell leukemia (HCL), large granular lymphocytic leukemia (LGL), t-cell acute lymphoblastic leukemia (T-ALL), Non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma,Multiple myeloma, Childhood Leukemia and Myelodysplastic-Myeloproliferative diseases.
Blood Cancer Treatment and Care
Treatment depends on many factors, including the type of cancer; age; how fast the cancer is progressing; where the cancer has spread; the symptoms and other health conditions. According to one of the most recent findings, researchers have come up with a curative alternative to blood cancer. The medication seeks to block the release of irregular enzymes accountable for the metastasis of blood cancer that are various therapies. Surfeit of protein accountable for the enlargement and increase of cancerous cells are likely to be blocked as well by the researched medication.
Different types of therapies such as Biological Therapy, Chemotherapy, Radiation Therapy
Stem Cell Transplantation, Targeted Therapy, Watchful Waiting, Clinical medicine and anticancer drugs, Gene therapy and Stem cells therapy will be discussed in this scientific session.
Blood Cancer and Risk Factors
A risk factor is anything that affects your chance of getting cancer. Different cancers have different risk factors. Some risk factors, such as smoking, can be controlled. Others, like your age or family history, can’t be changed. But having a risk factor, or even many risk factors, doesn’t mean you will get lymphoma and blood cancer. And many people who get the disease may not have any risk factors. In any case, having several risk factors can make you more likely to develop the disease. No one knows the exact causes of most lymphoma and blood cancers, especially leukemia. Physicians seldom know why one person develops cancer and another doesn’t. However, we do know that lymphoma and blood cancers aren’t contagious.
Primary risk factors and other associated factors for lymphoma and blood cancer are discussed in this session: Blood cancer and Anemia, Thrombosis,Blood Transfusion, Lymphatic System Defects, HIV Infection, Race and blood cancer,exposure to radiation and carcinogenic chemicals, Heredity/family history, Blood Cancer Risk Factors.
Immunology of Blood Cancer
Cancer immunology is a branch of immunology that studies interactions between the immune system and cancer cells (also called tumors or malignancies). It is a growing field of research that aims to discover innovative cancer immunotherapies to treat and retard progression of the disease. The immune response, including the recognition of cancer-specific antigens, is of particular interest in the field as knowledge gained drives the development of targeted therapy (such as new vaccines and antibody therapies) and tumor marker-based diagnostic tests.These scientific sessions will include the discussion on various topics such asImmunotherapeutic approaches , immune tolerance and deficiencies, Hematopoietic system, Lymphotoxin and immunotherapy.
Biomarkers for Blood Cancers
A cancer biomarker refers to a substance or process that is indicative of the presence of cancer in the body. A biomarker may be a molecule secreted by a tumor or a specific response of the body to the presence of cancer. Pharmacodynamics has proved to be new therapeutic window for biomarkers.Genetic, epigenetic, proteomic, glycomic and imaging biomarkers can be used for cancer diagnosis, prognosis, and epidemiology. Ideally, such biomarkers can be assayed in non-invasively collected bio fluids like blood or serum.It includes the discussion on different types of biomarkers available for blood cancer detection such as Clinical and non-clinical biomarkers, Blood biomarkers , Role of biomarkers in cancer research and medicine, Pharmacodynamics & pharmacokinetics and Emerging Biomarkers.
Blood Cancer Diagnosis
To confirm the presence of cancer and the severity or the stages of the cancer various cancer detection tests are carried out; certain cancer blood tests or other laboratory tests, such as an analysis of your urine or a biopsy of a suspicious area, to help guide the diagnosis. With the exception of blood cancers, blood tests generally can’t absolutely tell cancer or some other noncancerous condition, but they can give your doctor the clues about what’s going on inside the body.
Discussions will be carried out regarding the different tests performed to diagnose or confirm blood cancer: Complete blood count and Blood protein testing, Tumor marker tests and Biopsy, Cytogenetic, Imaging and Radiation Oncology, Endoscopy.
Experimental Cancer Treatments
Experimental cancer treatments are medical therapies intended or claimed to treat cancer by improving on, supplementing or replacing conventional methods. The twin goals of research are to determine whether the treatment actually works (called efficacy) and whether it is sufficiently safe. Stem Cell Transplantation is reserved for patients with life-threating diseases. Regulatory processes attempt to balance the potential benefits with the potential harms, so that people given the treatment are more likely to benefit from it than to be harmed by it.
Discussion of this scientific session includes the alternative and new experimental treatment procedures to treat cancer which includes: Stem Cell Transplant, Non -invasive Cancer Treatment, Telomerase therapy, Electromagnetic treatments and associated Clinical Trials and ethical issues.
Types of Blood Transfusions
Blood transfusions are a way to temporarily increase the number of blood cells. There are different types of blood transfusions to match the types of blood cells a patient may need. Transfusions are given to increase the blood’s ability to carry oxygen, restore the amount of blood in the body (blood volume), and correct clotting problems. People, who have been injured, people undergoing surgery, and people receiving treatment for cancers (such as leukemia) or other diseases (such as the blood diseases sickle cell anemia and thalassemia) are typical recipients.
In includes the discussion about different types of blood transfusions: Red blood Transfusions, Plasma Transfusions, Platelet Transfusion, Cryoprecipitate Transfusion, and white Blood Cell Transfusion.
Causes of Blood Cancer
The cause is usually different from other types of cancer. Experts say that Blood Malignancies arise due to different causes, some of them are suspected and some are yet to be. It is nearly impossible to prove what caused a blood cancer in any individual, because most blood cancers have multiple possible causes.
Discussions will be carried out on the suspecting and suspected causes of blood cancer that include: Exposure to radiation and chemicals, Genetic predisposition ,Exposure to certain drugs,, Human T-cell Leukemia Virus (HTLV),Electromagnetic energy, Genetic factors (chromosomal abnormalities, Maternal fetal transmission (rare).
Molecular Diagnostic Methods for Blood Cancer
Molecular diagnostic tests detect mutations in DNA or RNA that are associated with blood cancers. There are several molecular diagnostic techniques which are associated with a particular blood malignancy and are tested for a particular gene or a group of genes.According to the researchers, these diagnoses are useful for a significant percentage of the different types of blood cancer, since there are tumors in which a large amount of specific molecular markers or mutations are located.
In this section the molecular diagnostic methods Sanger and Pyro sequencing, Next generation sequencing , Allele Specific, Fragment Analysis and Oligonucleotide Analysis, , Multiplex Ligation Probe Amplification, , Amplification Refractory Mutation System, Different Types of PCR and Microarray, High Resolution Melt Analysis will be discussed.
Advances in blood cancer treatment
Today, there are over one million Americans living with, or in remission from, blood cancer, including leukemia, Hodgkin lymphoma, non-Hodgkin lymphoma and multiple myeloma. The field of hematologic oncology is rapidly evolving, and there are quite a few new and exciting treatment options for patients with hematologic malignancies.
Genomic testing examines a tumor on a genetic level to find the DNA alterations that are driving the growth of cancer. The FDA has approved new drugs for patients with hematologic malignancies. Another recent development in treating patients with hematologic cancer is attempting to use the patient’s own immune system and actually engineering the patient’s immune cells to target the disease. While this is under development in clinical trials, it’s another approach to eradicating any residual disease, particularly in CLL and ALL. Integrative approaches can significantly help in reducing side effects and improving quality of life for patients with hematologic malignancies.
The different types of advances like Genomic profiling for hematologic cancer, promising new drug options, Advances in stem cell transplantation, Integrative approach will be discussed.
Bone Marrow Transplantation and Biopsy Aspirations
A bone marrow transplant is a procedure to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Bone marrow is the soft, fatty tissue inside your bones. Stem cells are immature cells in the bone marrow that give rise to all of your blood cells. A biopsy is a sample of tissue taken from the body in order to examine it more closely. A doctor should recommend a biopsy when an initial test suggests that an area of tissue in the body isn’t normal. Doctors may call that area of abnormal tissue a lesion, a tumor, or a mass.Topics of discussion in the scientific sessions are Bone Marrow Stem Cell Therapy, Hematopoietic Cell, Blood and Marrow Transplantation, Bone marrow biopsy, Endoscopic biopsy and Needle biopsy.